Active substance
Chloroprocaine
- US FDA 9
- Health Canada 1
- Safety 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NESACAINE | 2% | injectable · injection | FRESENIUS KABI USA | Prescription | 11 Mar 1955 |
| NESACAINE-MPF | 2%; 3% | injectable · injection | FRESENIUS KABI USA | Prescription | 11 Mar 1955 |
| CHLOROPROCAINE HYDROCHLORIDE | 2%; 3% | injectable · injection | HIKMA PHARMS | Prescription | 9 Sep 1998 |
| IHEEZO | 3% | gel · ophthalmic | HARROW EYE | Prescription | 27 Sep 2022 |
| NESACAINE | 1% | injectable · injection | FRESENIUS KABI USA | Discontinued | 11 Mar 1955 |
| NESACAINE-MPF | 2%; 3% | injectable · injection | FRESENIUS KABI USA | Discontinued | 11 Mar 1955 |
| CHLOROPROCAINE HYDROCHLORIDE | 3% | injectable · injection | HOSPIRA | Discontinued | 16 Apr 1982 |
| CHLOROPROCAINE HYDROCHLORIDE | 2% | injectable · injection | HOSPIRA | Discontinued | 16 Apr 1982 |
| CLOROTEKAL | 50MG/5ML (10MG/ML) | solution · intrathecal | B BRAUN MEDICAL | Discontinued | 26 Sep 2017 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CLOROTEKAL | 02551063 | 10 MG / ML | SOLUTION · INTRATHECAL | B. BRAUN MELSUNGEN AG |
Safety signals and safety-related labeling changes
- US FDA 2 Nov 2018 NESACAINE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 2 Nov 2018 NESACAINE-MPF — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.